


# **CÁNCER HEREDITARIO: INVESTIGACIÓN TRANSLACIONAL**

Ana Osorio. Facultativo Servicio de Genética.  
IV REUNIÓN ANUAL DEL ÁREA DE GENÉTICA Y GENÓMICA  
DEL IIS-FJD  
29 de septiembre 2022


# Hereditary Breast and Ovarian Cancer (HBOC)




- Breast cancer
- Ovarian cancer

## Cancer risks for *BRCA1* and *BRCA2* mutation carriers

**A** Cumulative risk of first breast cancer among *BRCA1* and *BRCA2* mutation carriers



**B** Cumulative risk of ovarian cancer among *BRCA1* and *BRCA2* mutation carriers



**Average cumulative risks by age 80 years. Prospective cohort study of 6036 *BRCA1* and 3820 *BRCA2* female carriers.** Kuchenbaecker et al., JAMA. 2017 Jun 20;317(23):2402-2416.

# Breast cancer susceptibility: current model

Unexplained: 50%



Breat Cancer Association Consortium. N Engl J Med. 2021 Feb 4;384(5):428-439.

## Whole Exome Sequencing in Familial Breast Cancer

Rosa-Rosa, et al., PLoS One 2010	Spain	Not conclusive
Snape et al., Breast Cancer Res. Treat. 2011	U.K.	Not conclusive
Park et al., Breast Cancer Res. Treat. 2011	Australia, US	Not conclusive
Park et al., Am. J. Hum. Genet. 2012	Netherlands, Australia & Spain	<i>XRCC2?</i>
Thompson et al., Plos Genetics 2012	Australia & New Zealand	<i>FANCC &amp; BLM?</i>
Hilbers et al., PLoS One 2013	Netherlands	Not conclusive
Gracia-Aznarez et al., Plos One 2013	France, Italy, Netherlands, Australia & Spain	Not conclusive
Lynch et al., Breast J 2013	U.S.	Not conclusive
Wen et al., BMC Cancer 2014	U.S.	Not conclusive
Park et al., Cancer Discovery 2014	U.S. & Australia	<i>RINT1?</i>
Kiiski et al., PNAS 2014	Finland	<i>FANCM?</i>
Cybulsky et al., Nat. Genet. 2015	Poland & Quebec	<i>RECQL?</i>
Sun et al., PLoS Genetics 2015	China	<i>RECQL?</i>
Noh et al., Radiat Oncol 2015	Korea	Not conclusive
Maatta et al., Eur J Human Genet 2017	Finland	Not conclusive
Jalkh et al., BMC Med Genomics 2017	Lebanon	Not conclusive
Kim et al., PLoS One 2017	Egypt	Not conclusive
Tavera-Tapia et al., Human Mutation 2019	Spain	<i>RECQL5?</i>
Felicio et al., 2021 et al., Human Mutation 2021	Brazil	Not conclusive

*cnio* stop cancer



## Research projects:


1. **Optimizing masive sequencing strategies for the identification and clinical translation of new susceptibility genes implicated in familial breast cancer (PI19/00640, 2019-2023).**
2. **Impact of incorporating PRS and mammographic density in BC risk stratification in *ATM*, *BARD1*, *CHEK2*, *RAD51C*, *RAD51D* and *PALB2* mutations carriers (Dr. de la Hoya, HCSC & GEICAM)**
3. **Exploring the mechanism of action of PARP inhibitors in *BRCA1/2* mutation carriers.**

## **Collaborations**


1. **CIMBA consortium (Consortium of Investigators of Modifiers of BRCA1/2), Cambridge University.**
2. **MERGE (Male Breast Cancer Genetics Consortium), Belfast University.**
3. **IMPACT-GENÓMICA (WP4).**

# cnag 2013, 300 exomes to elucidate rare diseases


Family 1




Family 3



Family 2



Family 4



Tavera-Tapia et al., Breast Cancer Res Treat. 2017 Feb;161(3):597-604  
Tavera-Tapia et al., Hum Mutat. 2019 May;40(5):566-577

## PI19/00640, 2019-2023

### Patients:

- ✓ 2500 BRCA1 families selected by phenotype. Minimum criteria: a) at least 2 women affected with BC, at least one <50y or b) at least one MBC. "Extreme" phenotypes were prioritized
- ✓ Proceeding from:
  - CNIO
  - Hospital Clínico San Carlos (Madrid)
  - Hospital La Mancha Centro (Ciudad Real)
  - Hospital General de Ciudad Real
  - Complejo Hospitalario de Albacete
  - Hospital Virgen de la Luz (Cuenca)
  - Universidad de Valladolid

### Controls:



Data from ~50,000 European non-Finnish individuals (gnomAD v2.1.1 )  
Collaborative Spanish Variant Server (CSVS) (<http://csvs.clinbioinfospa.es/>)

### Genes

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19



# NGS using Nextera Flex for Enrichment with IDT probes



Anne Parra Heming  
(Master student 2020)



Beatriz Benito Sánchez  
(Master student 2021)



Erik Marchena Perea  
(PhD student from 2021)



Milton Salazar Hidalgo  
(Master student 2022)

## MAIN RESULTS 1: HELICASES



*cancers*



*Article.*

# A large case-control study performed in Spanish population suggests that *RECQL5* is the only RECQ helicase involved in breast cancer susceptibility

Marchena-Perea EM<sup>1</sup>, Salazar-Hidalgo M<sup>1</sup>, Gómez-Sanz A<sup>2</sup>, Arranz-Ledo M<sup>3</sup>, Barroso A<sup>1</sup>, Fernández V<sup>1</sup>, Tejera-Pérez H<sup>4</sup>, Pita G<sup>4</sup>, Núñez-Torres R<sup>4</sup>, Pombo L<sup>5</sup>, Morales-Chamorro R<sup>6</sup>, Cano-Cano JM<sup>7</sup>, Soriano MC<sup>8</sup>, Garre P<sup>2</sup>, Durán M<sup>3</sup>, Currás-Freixes M<sup>1</sup>, de la Hoya M<sup>2</sup> and Osorio A<sup>\*1,9</sup>

## **Future plans**

- ✓ **To finish the genetics analysis and the case-control studies for the new candidate genes (Erik Marchena`s PhD project to be finished in December 2022)**
- ✓ **To ask for funding to establish the role of the candidate BC susceptibility genes by.**
  - 1. Performing structural and functional analysis of the candidate variants**
  - 2. Validating the results in a new BRCA1 series.**
- ✓ **To continue with all the collaborative projects (already preparing documents)**